Prior studies have shown decreases in stroke mortality over time, but data on validated stroke incidence and long-term trends by race are limited.
rious physical and cognitive long-term disability in adults.
2 Almost 800 000 US residents experience an incident or recurrent stroke each year, and more than 600 000 of these are first-ever events. 3 Stroke incidence varies by sex and ethnic group. [4] [5] [6] A decrease in stroke incidence rates in recent decades has been shown in several countries. [7] [8] [9] [10] However, reports on changes in sex-specific and race-specific incidence and casefatality rates over time are not consistent. The reported ageadjusted incidence of first ischemic stroke is more than twice as high in black as in white participants. The black vs white incidence rate ratio (IRR) is highest at midlife and decreases thereafter. 3 Studies from the United States and the United Kingdom have generally shown a decline in stroke incidence for the white population. 5, 11, 12 Some studies 5, 12 have shown no changes in stroke incidence in the black population, whereas others reported a decline in stroke incidence in black women, but not men. 11 Trends in incidence and 30-day mortality over several decades in 9152 Framingham Heart Study participants show a decrease in lifetime risk of stroke, along with a decline in 30-day mortality in men between 1950 and 2004. 4 The ageadjusted rate of mortality after stroke decreased by 37% from 1999 to 2009 in the United States. 1 The decline in mortality was greater for men than women overall, but lower in black men compared with other groups. 3 Previous studies from the Atherosclerosis Risk in Communities (ARIC) study cohort found the highest age-adjusted stroke incidence rates among black men, followed by black women, white men, and white women. 13 Age-adjusted casefatality rates tended to be higher among black participants and men. We report here long-term temporal trends through 2011 in stroke incidence and subsequent short-and long-term mortality by race, sex and age-group, based on 24 years of follow-up among black and white adults in the ARIC prospective cohort study.
Methods

Study Population
The Atherosclerosis Risk in Communities (ARIC) study is a prospective study of 15 792 residents in 4 US communities aged 45 to 64 years at baseline (1987) (1988) (1989) , 13 designed to investigate variation in cardiovascular diseases by race, sex, location, and date. Informed consent was obtained and procedures were approved by institutional review boards at all centers from which there were participants. Information on cardiovascular risk factors and self-reported race was collected at baseline through interviews and physical examinations.
14 Follow-up was carried out through examinations (1990-1992, 1993-1995, and 1996-1998) , annual phone interviews, and active surveillance of discharges from local hospitals.
Ascertainment of Stroke Events and Vital Status
All stroke hospitalizations and deaths from 1987 to 2011 occurring in ARIC participants were identified. Hospital records for possible stroke-related hospitalizations were obtained (In- Definition of Stroke Incidence and Subsequent Short-and Long-term Mortality
An incident stroke was defined as a first definite or probable stroke in a participant with no physician-diagnosed stroke at the baseline interview. Subsequent short-and long-term mortality were defined as hazard of death due to all causes within 30-day, 1-year, and 5-year periods and by the end of follow-up after the incident stroke.
Definition of Covariates
Sociodemographic and behavioral risk factors were selfreported at baseline and updated during follow-up examinations and phone interviews. Smoking status was classified in 3 categories: never, former, or current. Participants were screened for hypertension and diabetes at the study visits, as well as asked for use of medications for these conditions. For hypertension, the average of last 2 of 3 seated blood pressure levels measured after 5 minutes of rest using a random-zero sphygmomanometer was reported. Prevalent hypertension was defined as average systolic of at least 140 mm Hg or average diastolic blood pressure of at least 90 mm Hg, self-reported diagnosis of hypertension by a physician, or use of hypertension medication. Prevalent diabetes was defined by selfreported diagnosis of diabetes by a physician or treatment for diabetes, a fasting glucose level of at least 126 mg/dL, or a casual blood glucose level of at least ≥200 mg/dL. Coronary heart disease (CHD) was defined by self-reported physician diagnosis of myocardial infarction (MI) or coronary revascularization, or by electrocardiographic evidence of a prior MI. Cholesterol-lowering medications use was self-reported and confirmed by review of medications brought to each follow-up visit. Time-varying hypertension and diabetes were updated using annual telephone calls based on self-reported physician diagnosis or use of hypertension or diabetes medication. CHD, cholesterol-lowering medications use, and smoking status were time-varying covariates as well.
Statistical Analysis
Characteristics of participants at baseline (ARIC visit 1, [1987] [1988] [1989] and follow-up (ARIC visit 4, 1996-1998) were presented for the entire sample as well as for the 55-to 64-year-old group, which overlaps all time periods. Prevalence of time-varying risk factors at baseline and visit 4 was compared using ageadjusted prevalence rate ratios (RRs) and 95% CIs. Incidence rates (IRs) and 95% CIs of total and ischemic definite or probable stroke per 1000 person-years were calculated and modeled with Poisson regression, stratifying age by 5-year groups and calendar time by 3-year periods corresponding to the ARIC visit intervals. In order to include the most updated data available, the last period was defined as a 4-year Copyright 2014 American Medical Association. All rights reserved.
period (2008) (2009) (2010) (2011) . Tables presenting IRs report the 1990-2011 time frame, after recruitment was complete. Incidence rate ratio estimates were adjusted for age and calendar time period in model 1, additionally adjusted for sex and race/center (demographic variables) and hypertension, diabetes, CHD, cholesterol-lowering medications use, and smoking status (timevarying prevalence of risk factors) in model 2, and were computed overall and stratified by race, sex, and age (categorized as younger than 65 years and 65 and older). These subgroup comparisons were preplanned. Interactions between linearly modeled calendar time and race, sex, and age-group were assessed. The adjusted IRRs (95% CIs) were graphed for incident stroke for the age groups of younger than 65 years and also for 65 years and older, with calendar time modeled categorically and linearly.
Thirty-day, 1-year, 5-year and end of follow-up hazard ratios (HRs) and 95% CIs were analyzed using Cox proportional hazards regression models, adjusting for time-dependent prevalent risk-factors. No violations of proportionality were observed. Models stratified by race, sex, and age at stroke incidence (<65 and ≥65 years) were presented and interactions tested.
All participants included in this analysis had complete baseline data for age, sex, race, center, smoking status, hypertension, diabetes, CHD, and cholesterol-lowering medications use. If a participant missed a visit or a follow-up telephone call, the last value for time-varying smoking status, diabetes, hypertension, and cholesterol-lowering medications use was carried forward. Missing data rate was less than 2.5% for each of these variables at the visits and less than 10% at each annual follow-up call. Based on the low rates of missing data for covariates, this analysis used a complete data model. All tests were 2-sided and a P value of less than .05 was considered statistically significant. Stata version 13 (StataCorp) was used for data analysis.
Results
Participants' Characteristics
The present analysis included 14 357 ARIC participants after excluding individuals with prevalent stroke (n = 779), individuals who were not black or white (suburban Minneapolis Minnesota and Washington County, Maryland limited to white participants; n = 96), or individuals with missing data on prevalence of CHD (n = 271), diabetes (n = 122), hypertension (n = 76), cholesterol-lowering medications use (n = 79), or smoking status (n = 12). Demographic characteristics of participants and prevalence of cardiovascular risk factors are shown in Table 1 . At baseline, mean (SD) age was 54.1 (5.8) years and 55.4% of the participants were women. Hypertension was present in more than one-third of participants, 11.6% had diabetes, 2.8% used cholesterol-lowering medications, and 25.9% reported current smoking. At 9-year follow-up (visit 4), reported use of cholesterol-lowering medications was more than 5 times higher than at baseline (14.3% vs 2.8%). In addition, there was a 40% increase in the proportion of hypertension and diabetes, and 80% increase in CHD prevalence, while the rate of current smoking substantially decreased to 14.7%. Comparison of a subset of participants in the same age-group (55-64 years) at both visits showed a 3.3-fold increase in cholesterol-lowering medications use, but similar proportions of hypertension, diabetes, and CHD in both visits. The rate of smoking was lower and education and income were significantly higher among participants in the younger birth cohort (age 55-64 years at visit 4). Age-adjusted prevalence rate ratios for the entire study period (visit 1-end of follow-up) (PRRs, 95% CIs) for timevarying risk-factors were 0.66 (95% CI, 0.64-0.68) for current smoking, 1.24 (95% CI, 1.23-1.26) for hypertension, 1.36 (95% CI, 1.33-1.39) for diabetes, 1.01 (95% CI, 0.98-1.04) for CHD and 3.03 (95% CI, 2.96-3.09) for cholesterol-lowering medications use.
Stroke Incidence
Definite or probable incident stroke was diagnosed in 1051 of 14 357 participants (7%) during 282 097 person-years of follow-up from 1987 to 2011. In total, 929 participants had incident ischemic stroke and 140 had incident hemorrhagic stroke. Eighteen of the 1051 participants with incident stroke had both a first-ever ischemic and a first-ever hemorrhagic stroke during the study period. Median (interquartile range [IQR]) length of follow-up was 22.5 (17.4-23.5) years. Losses to follow-up were less than 1% annually for the follow-up calls used to determine hospitalization and hence stroke incidence. From recruitment (1987) (1988) (1989) to the end of follow-up for this study (December 31, 2011), the cumulative loss to follow-up (participants alive with no stroke and censored before December 31, 2011) was 4.4% (638/14 357 participants). Crude incidence rates were 3.73 (95% CI, 3.51-3.96) per 1000 person-years for total stroke, 3.29 (95% CI, 3.08-3.50) per 1000 person-years for ischemic stroke, and 0.49 (0.41-0.57) per 1000 person-years for hemorrhagic stroke. Incidence rates were greater with increasing age and often decreased across calendar time periods within a given age category, with the clearest pattern at age 70 to 79 years, and less clear patterns in other rows including a suggestion of less decline at younger ages and random variation in some small cells ( Table 2 ). Crude incidence rates of ischemic stroke showed similar trends (eTable 1 in the Supplement). The decrease in risk of stroke with time was reflected by the incidence rate ratios (IRRs) shown in Table 3 . IRRs per 10-year period were 0.76 (95% CI, 0.66-0.87; absolute decrease of 0.93 per 1000 personyears) adjusted for age and 0.71 (95% CI, 0.62-0.83; absolute decrease of 1.16 per 1000 person-years) adjusted for age, other demographic variables, and time-varying prevalence of riskfactors. Stroke IRRs for a 10-year increase in age were 2.15 (95% CI, 1.93-2.39; absolute increase of 1.82 per 1000 person-years) adjusted for calendar time and 2.03 (95% CI, 1.82-2.26; absolute decrease of 1.72 per 1000 person-years) additionally adjusted for demographic variables and time-varying prevalence of risk factors. Stroke incidence was strongly related to older age, male sex, black race, hypertension, diabetes, CHD, and current smoking, and negatively associated with cholesterol-lowering medications use.
In the stratified analysis (Table 3) . HRs for all-cause mortality after stroke at each of these periods are presented in Table 4 , and hazard estimates related to covariates are shown in eTable 3 in the Supplement. Overall, age-adjusted mortality after stroke decreased over time (HR, 0.80; 95% CI, 0.66-0.98 per 10-year period; absolute decrease of 8.09 per 100 strokes after 10 years).
Precision increased along with longer follow-up, and the decrease in mortality was mostly accounted for by the decrease for the younger than 65 years age group (HR, 0.65; 95% CI, 0.46-0.93; absolute decrease of 14.19 per 100 strokes after 10 years), but was similar across sex and race, except for a suggestion of steeper decline among white participants in the full followup. Adjustment did not significantly change the results; however, use of cholesterol-lowering medications was associated with lower mortality (HR, 0.69; 95% CI, 0.57-0.84), whereas higher mortality hazards were associated with diabetes (HR, 1.48; 95% CI, 1.25-1.75), CHD (HR, 1.45; 95% CI, 1.22-1.73), and current smoking (HR, 1.37; 95% CI, 1.07-1.75). Test for interaction suggests that differences in 30-day mortality by age may be large, but precision was limited; and that long-term mortality (>5-year) trends may be less steep in black participants. Secondary analysis of the trends in stroke, as the underlying cause of death among all participants, showed a decline over time as well (HR, 0.64; 95% CI, 0.46-0.89 per 10 years).
Discussion
In this cohort of 4 US communities, this study demonstrated a significant decrease in stroke incidence from 1987 to 2011 in white and black participants and in men and women. However, the decrease in stroke incidence was observed only at ages older than 65 years. Stroke mortality decreased as well. This decrease was generally similar in men and women and by race. In contrast to incidence trends, the steepest stroke mortality decrease was found at younger age.
Comparison With Other Studies
Trends in Stroke Incidence Substantial decreases in stroke incidence had been reported in the United States before the establishment of the ARIC study. 15, 16 Data from the Framingham Study 4 and the Greater Cincinnati/Northern Kentucky Stroke Study 5 showed the de- study, which adjusted for calendar time and age simultaneously, showed a significant decrease in stroke incidence from 1987 to 2011 in the ARIC cohort. The decrease in rates was not consistent for all age groups. In fact, no decrease in incidence rates was observed for younger participants (aged <65 years). This is consistent with a study from Sweden, 21 which reported a decrease in stroke incidence limited to older ages as well as with other reports of a lower mean age at stroke. 22, 23 Data from the Greater Cincinnati/Northern Kentucky Stroke Study showed a significant decrease in stroke incidence in 2005, when compared with 1993-1994 and 1999, driven by a decrease in incidence in white participants only. 5 In ARIC, the decrease in stroke incidence was similar in black and white participants. Among black participants, discordance in trend estimates across studies could be due to differences in risk factors distribution in geographically diverse communities. The ARIC data provided new evidence that at least among some black communities in the South, stroke incidence had declined from 1987 to 2011. Similarity by sex in this study was consistent with previous reports on US stroke trends. 
Potential Reasons for the Decrease in Stroke Incidence and Mortality
More successful control of risk factors in the last decades (mainly hypertension control starting in the 1970s and later hypertension treatment combined with smoking cessation, control of diabetes and dyslipidemia, and treatment of atrial fibrillation) may have resulted in lower stroke incidence and less severe strokes, 27 which may account for the observed lower mortality rates. 25 In the cohort for this study, age-adjusted rates of hypertension and diabetes increased between ARIC visits. Use of cholesterol-lowering medications, which decreased stroke risk and mortality in trials 28, 29 and showed similar associations in ARIC, increased. In contrast to hypertension and diabetes, current smoking decreased, so the overall effect of adjustment for prevalent risk factors was relatively small; however, this study could not quantify the intensity of treatment for risk factors. In addition to better control of risk factors, the use of reperfusion therapy for acute ischemic stroke has increased since treatment with tissue plasminogen activator was approved in the United States in 1996 and postacute management strategies have improved over time.
Factors related to short-and long-term mortality after stroke differ. Comorbidities and factors associated with atherosclerotic vascular disease have been shown to predict longterm mortality, whereas stroke characteristics have been associated with short-term mortality. 30 The increased hazards of mortality at 5 years and over after stroke incidence observed in association with diabetes and CHD support these previous findings.
In contrast with the greater decline in stroke incidence at age older than 65 years, the decrease in short-and long-term mortality, adjusted for age and other time-varying prevalent risk factors, was driven by reductions at age younger than 65 years rather than at age of 65 years and older. Less improvement in mortality after strokes at older ages may be related to estimates that withdrawal of care accounted for approximately 40% of the observed early stroke excess mortality among older patients compared with younger ones. 31 
Strengths and Limitations
The prospective ARIC cohort study allows for collection of accurate data on time-varying prevalence of cardiovascular risk factors, stroke incidence, and mortality in 4 US communities. The prolonged follow-up of this large biracial cohort provided detailed information for the study of stroke trends by sex, age-group, race, and study center. ARIC was designed to 
